Maxalt Rapitab (Rizatriptan Benzoate)

Rizatriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors in the brain. This action causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerves, thereby interrupting the pain pathway that drives migraine.

The specific dose of Maxalt Rapitab is determined by the prescribing healthcare professional based on the individual’s clinical condition, previous response to therapy, and any contraindications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for rizatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To order Maxalt Rapitab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maxalt Rapitab (rizatriptan) is a second‑generation triptan with a rapid onset of action, typically providing relief within 30‑60 minutes. Compared with older triptans such as sumatriptan, rizatriptan may have a slightly higher efficacy for some patients and is available as an orally disintegrating tablet, which can be convenient for those with nausea.

Store Maxalt Rapitab at ambient temperature, preferably below 25 °C, in its original blister pack. Keep the tablets away from moisture, direct sunlight and heat sources. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Maxalt Rapitab is an orally disintegrating tablet that is placed on the tongue and allowed to dissolve without water. It should be taken as soon as the migraine attack begins, preferably before the pain becomes severe, and patients should avoid eating or drinking for a few minutes after dissolution.

Serious risks include chest pain or tightness that may signal coronary vasospasm, serotonin syndrome when combined with other serotonergic agents, and severe allergic reactions such as rash, swelling or breathing difficulty. Patients experiencing any of these symptoms should seek immediate medical attention.

Maxalt Rapitab should be avoided in patients with uncontrolled cardiovascular disease, recent myocardial infarction, severe hypertension, a history of stroke or transient ischemic attack, and in those taking MAO inhibitors within the past 14 days. It is also contraindicated in patients with known hypersensitivity to rizatriptan or any tablet excipients.